(Q50632272)

16 March 2018

title

Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. (English)

1 reference

16 March 2018

1 reference

1 reference

1

1 reference

16 March 2018

Madia Lozupone

Madia Lozupone

5

0 references

Giancarlo Logroscino

13

Giancarlo Logroscino

1 reference

16 March 2018

Bruno P Imbimbo

4

1 reference

ORCID Public Data File 2021

Vincenzo Solfrizzi

2

Vincenzo Solfrizzi

1 reference

16 March 2018

Davide Seripa

3

Davide Seripa

1 reference

16 March 2018

Andrea Santamato

6

Andrea Santamato

1 reference

16 March 2018

Rosanna Tortelli

7

Rosanna Tortelli

1 reference

16 March 2018

author name string

Ilaria Galizia

8

1 reference

16 March 2018

Camilla Prete

9

1 reference

16 March 2018

Antonio Daniele

10

1 reference

16 March 2018

Alberto Pilotto

11

1 reference

16 March 2018

Antonio Greco

12

1 reference

16 March 2018

publication date

1 September 2016

1 reference

16 March 2018

published in

Immunotherapy

1 reference

16 March 2018

volume

8

1 reference

16 March 2018

issue

9

1 reference

16 March 2018

page(s)

1119-1134

1 reference

16 March 2018

2015 Alzheimer's disease facts and figures

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau-aggregation inhibitor therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau protein kinases: involvement in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau immunotherapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau in Alzheimer disease and related tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Frequency of stages of Alzheimer-related lesions in different age categories

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Biomarkers in dementia: clinical utility and new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Structural characterization of the core of the paired helical filament of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Acetylation of tau inhibits its degradation and contributes to tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

The roles of intracellular protein-degradation pathways in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Propagation of tau misfolding from the outside to the inside of a cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Transmission and spreading of tauopathy in transgenic mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Propagation of tau pathology in a model of early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Mechanisms of tau-induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau reduction prevents Abeta-induced defects in axonal transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Multiple-motor based transport and its regulation by Tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Convergence of amyloid-beta and tau pathologies on mitochondria in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Further understanding of tau phosphorylation: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Defective brain microtubule assembly in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

NAP (davunetide) provides functional and structural neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

NAP alpha-aminoisobutyric acid (IsoNAP).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Structure and mechanism of action of tau aggregation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Structural determinants of Tau aggregation inhibitor potency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Dimethyl fumarate : a Janus-faced substance?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau-targeted treatment strategies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Trans-cellular propagation of Tau aggregation by fibrillar species

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Human secreted tau increases amyloid-beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Alzheimer's pathogenesis: is there neuron-to-neuron propagation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Anti-tau antibody reduces insoluble tau and decreases brain atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Direct cellular delivery of human proteasomes to delay tau aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Configuration-specific immunotherapy targeting cis pThr231-Pro232 tau for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0019

21 January 2018

Identifiers

DOI

10.2217/IMT-2016-0019

1 reference

16 March 2018

1 reference

16 March 2018